Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish company’s CagriSema drug fell short of investors’ expectations.
Digital access for organisations. Includes exclusive features and content.
，推荐阅读safew官方版本下载获取更多信息
Угрозу применения ядерного оружия в конфликте вокруг Ирана оценили14:57
Department of Psychology, Princeton University